WO2010007316A3 - NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET - Google Patents

NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET Download PDF

Info

Publication number
WO2010007316A3
WO2010007316A3 PCT/FR2009/051406 FR2009051406W WO2010007316A3 WO 2010007316 A3 WO2010007316 A3 WO 2010007316A3 FR 2009051406 W FR2009051406 W FR 2009051406W WO 2010007316 A3 WO2010007316 A3 WO 2010007316A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
medicaments
preparation
pharmaceutical compositions
met inhibitors
Prior art date
Application number
PCT/FR2009/051406
Other languages
English (en)
Other versions
WO2010007316A2 (fr
Inventor
Eric Bacque
Dominique Damour
Conception Nemecek
Patrick Nemecek
Sylvie Wentzler
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010007316(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0804084A external-priority patent/FR2933980B1/fr
Priority claimed from FR0900245A external-priority patent/FR2941229B1/fr
Priority to BRPI0916464-2A priority Critical patent/BRPI0916464A2/pt
Priority to JP2011517978A priority patent/JP2011528337A/ja
Priority to EP09736253A priority patent/EP2310366A2/fr
Priority to EA201170222A priority patent/EA201170222A1/ru
Priority to CN2009801365397A priority patent/CN102159543A/zh
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to MX2011000671A priority patent/MX2011000671A/es
Priority to CA2730959A priority patent/CA2730959A1/fr
Priority to AU2009272516A priority patent/AU2009272516A1/en
Priority to US13/054,663 priority patent/US20110263594A1/en
Publication of WO2010007316A2 publication Critical patent/WO2010007316A2/fr
Publication of WO2010007316A3 publication Critical patent/WO2010007316A3/fr
Priority to IL210688A priority patent/IL210688A0/en
Priority to MA33625A priority patent/MA32570B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

L'invention concerne les nouveaux produits de formule (I): dans laquelle : Ra représente H, HaI, aryle ou hétéroaryle éventuellement substitués; Rb représente H, Rc, -COORc,-CO-Rc ou -CO-NRcRd; avec Rc représente alkyle, cycloalkyle, hétérocycloalkyle, aryle et hétéroaryle, tous éventuellement substitués; Rd représente H, alk ou cycloalkyle; ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments notamment comme inhibiteurs de MET.
PCT/FR2009/051406 2008-07-18 2009-07-16 NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET WO2010007316A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2730959A CA2730959A1 (fr) 2008-07-18 2009-07-16 Nouveaux derives triazolo[4,3-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AU2009272516A AU2009272516A1 (en) 2008-07-18 2009-07-16 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
JP2011517978A JP2011528337A (ja) 2008-07-18 2009-07-16 新規トリアゾロ［４，３−ａ］ピリジン誘導体、これらの調製方法、医薬としてのこれらの使用、医薬組成物および、特にｍｅｔ阻害剤としての、新規使用
US13/054,663 US20110263594A1 (en) 2008-07-18 2009-07-16 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
EP09736253A EP2310366A2 (fr) 2008-07-18 2009-07-16 NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
EA201170222A EA201170222A1 (ru) 2008-07-18 2009-07-16 НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ
CN2009801365397A CN102159543A (zh) 2008-07-18 2009-07-16 新颖的三唑并[4,3-a]吡啶衍生物，其制备方法，其作为药物的用途，药物组合物及新颖的尤其是作为MET抑制剂的用途
BRPI0916464-2A BRPI0916464A2 (pt) 2008-07-18 2009-07-16 derivados triazolo(4,3-a) piridina, o respectivo processo de preparo, a respectiva aplicação como medicamentos, composições farmacêuticas e utilização notadamente como inibidores de met
MX2011000671A MX2011000671A (es) 2008-07-18 2009-07-16 Nuevos derivados de triazolo [4,3-a] piridina su procedimiento de preparacion, su uso como medicamentos, composiciones farmaceuticas y nuevo uso particularmente como inhibidores de met.
IL210688A IL210688A0 (en) 2008-07-18 2011-01-16 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
MA33625A MA32570B1 (fr) 2008-07-18 2011-02-15 NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0804084 2008-07-18
FR0804084A FR2933980B1 (fr) 2008-07-18 2008-07-18 Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR0900245A FR2941229B1 (fr) 2009-01-21 2009-01-21 Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR0900245 2009-01-21

Publications (2)

Publication Number Publication Date
WO2010007316A2 WO2010007316A2 (fr) 2010-01-21
WO2010007316A3 true WO2010007316A3 (fr) 2010-04-29

Family

ID=41550767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/051406 WO2010007316A2 (fr) 2008-07-18 2009-07-16 NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Country Status (19)

Country Link
US (1) US20110263594A1 (fr)
EP (1) EP2310366A2 (fr)
JP (1) JP2011528337A (fr)
KR (1) KR20110039558A (fr)
CN (1) CN102159543A (fr)
AR (1) AR072819A1 (fr)
AU (1) AU2009272516A1 (fr)
BR (1) BRPI0916464A2 (fr)
CA (1) CA2730959A1 (fr)
CL (1) CL2011000119A1 (fr)
CO (1) CO6331463A2 (fr)
EA (1) EA201170222A1 (fr)
IL (1) IL210688A0 (fr)
MA (1) MA32570B1 (fr)
MX (1) MX2011000671A (fr)
PE (1) PE20110560A1 (fr)
TW (1) TW201008938A (fr)
UY (1) UY31996A (fr)
WO (1) WO2010007316A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
US9127000B2 (en) * 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
AU2014262326B2 (en) * 2013-05-10 2018-03-22 Jiangsu Hansoh Pharmaceutical Co., Ltd. [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof
EP3004095A1 (fr) * 2013-06-03 2016-04-13 Bayer Pharma Aktiengesellschaft Triazolopyridines utilisées comme inhibiteurs de la thrombine pour traiter des maladies thromboemboliques
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016089648A1 (fr) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
CN106489962B (zh) * 2016-10-20 2019-02-22 贵州大学 一种[1,2,4]三唑[4,3-a]吡啶类含硫化合物在制备杀虫剂中的应用
AU2018378935A1 (en) 2017-12-07 2020-06-25 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857371A (en) * 1954-09-10 1958-10-21 Eastman Kodak Co Benzothiazole azo diphenylamine compounds
EP0048555A1 (fr) * 1980-08-27 1982-03-31 Glaxo Group Limited Dérivés aminés du 1,2,4 triazole, leur procédé de préparation et médicaments les contenant
EP0254623A1 (fr) * 1986-07-23 1988-01-27 Laboratoires Upsa Nouveaux dérivés amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procédés de préparation, médicaments les contenant, utiles notamment comme antalgiques
US20060057510A1 (en) * 2004-09-07 2006-03-16 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
WO2007075567A1 (fr) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase
WO2008092888A1 (fr) * 2007-02-01 2008-08-07 Glaxo Group Limited Dérivés 1-oxa-3-azaspiro [4,5] décane-2-one pour le traitement de troubles de l'alimentation
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857371A (en) * 1954-09-10 1958-10-21 Eastman Kodak Co Benzothiazole azo diphenylamine compounds
EP0048555A1 (fr) * 1980-08-27 1982-03-31 Glaxo Group Limited Dérivés aminés du 1,2,4 triazole, leur procédé de préparation et médicaments les contenant
EP0254623A1 (fr) * 1986-07-23 1988-01-27 Laboratoires Upsa Nouveaux dérivés amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procédés de préparation, médicaments les contenant, utiles notamment comme antalgiques
US20060057510A1 (en) * 2004-09-07 2006-03-16 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
WO2007075567A1 (fr) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase
WO2008092888A1 (fr) * 2007-02-01 2008-08-07 Glaxo Group Limited Dérivés 1-oxa-3-azaspiro [4,5] décane-2-one pour le traitement de troubles de l'alimentation
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMCATS, [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 December 2008 (2008-12-04), SPECS: "Compounds for screening", XP002543539, retrieved from CHEMCATS *
EDMONDSON, SCOTT D. ET AL: "(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4- [1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A selective .alpha.-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 12, 2006, pages 3614 - 3627, XP002543538, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
TW201008938A (en) 2010-03-01
KR20110039558A (ko) 2011-04-19
JP2011528337A (ja) 2011-11-17
PE20110560A1 (es) 2011-08-29
WO2010007316A2 (fr) 2010-01-21
BRPI0916464A2 (pt) 2018-06-12
MX2011000671A (es) 2011-04-11
US20110263594A1 (en) 2011-10-27
CA2730959A1 (fr) 2010-01-21
CO6331463A2 (es) 2011-10-20
MA32570B1 (fr) 2011-08-01
CL2011000119A1 (es) 2011-06-17
UY31996A (es) 2010-02-26
AR072819A1 (es) 2010-09-22
CN102159543A (zh) 2011-08-17
IL210688A0 (en) 2011-03-31
EP2310366A2 (fr) 2011-04-20
AU2009272516A1 (en) 2010-01-21
EA201170222A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
WO2010007316A3 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
EA201170223A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ
WO2011138751A3 (fr) Dérivés hétérocycliques destinés au traitement de maladies
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
WO2010007318A3 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
WO2008013838A3 (fr) Dérivés de pyridizinone
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
BRPI0916385A2 (pt) derivados de carbamatos de alquiltiazóis, sua respectiva preparação e sua respectiva aplicação em terapêutica
WO2008030744A3 (fr) Inhibiteurs de c-met et leurs utilisations
WO2007065664A3 (fr) Acides pyrazolo[1,5-a]pyridine-3-carboxyliques utilises en tant qu’inhibiteurs de la ephb et vegfr2 kinase
TW200732323A (en) Organic compounds
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
NO20085212L (no) Nye pyridinanaloger
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
WO2009080705A3 (fr) Composés organiques
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
WO2010027236A3 (fr) Composé hétérocyclique condensé
WO2011132051A3 (fr) Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
WO2009021965A3 (fr) Composés
WO2013177534A3 (fr) Nouveaux dérivés d'acide salicylique, sel de qualité pharmaceutique correspondant, composition et procédé d'utilisation correspondants
WO2009094560A3 (fr) Thiénopyranones en tant qu'inhibiteurs de kinase
WO2008009750A3 (fr) Composés macrocycliques utiles comme inhibiteurs de la bace
WO2008046982A3 (fr) Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7
GB0602951D0 (en) Organic Compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980136539.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09736253

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 113/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2730959

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011517978

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009736253

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 590549

Country of ref document: NZ

Ref document number: 000048-2011

Country of ref document: PE

Ref document number: 12011500119

Country of ref document: PH

Ref document number: MX/A/2011/000671

Country of ref document: MX

Ref document number: 2009736253

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11004610

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009272516

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2011000080

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2009272516

Country of ref document: AU

Date of ref document: 20090716

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117003697

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201170222

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13054663

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0916464

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110117